-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ISN-001 in Fecal Incontinence
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ISN-001 in Fecal Incontinence Drug Details: ISN-001 (ALLO-ASC) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Drug Details: Nemvaleukin alfa...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Not Disclosed Pain in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Not Disclosed Pain in PainDrug Details:The drug candidate is under development for the treatment of pain.Report...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Rotavirus (Trivalent) Vaccine in Rotavirus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Rotavirus (Trivalent) Vaccine in Rotavirus InfectionsDrug Details:The vaccine candidate is under development for the prevention...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07911145 in Herpes Zoster (Shingles)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PF-07911145 in Herpes Zoster (Shingles)Drug Details: PF-07911145 is under development for the prevention of shingles (herpes...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LY-3819469 in Atherosclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LY-3819469 in Atherosclerosis Drug Details: LY-3819469 (DCR-CM2) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOXR-1030 in Myxoid Liposarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BOXR-1030 in Myxoid LiposarcomaDrug Details:BOXR-1030 is under development for the treatment of hepatocellular carcinoma, lung squamous...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOXR-1030 in Round Cell Liposarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BOXR-1030 in Round Cell LiposarcomaDrug Details:BOXR-1030 is under development for the treatment of hepatocellular carcinoma, lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Estradiol + Progesterone) in Vasomotor Symptoms of Menopause (Hot Flashes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Estradiol + Progesterone) in Vasomotor Symptoms of Menopause (Hot Flashes) Drug Details:Estradiol in combination with progesterone...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOXR-1030 in Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BOXR-1030 in Lung Cancer Drug Details:BOXR-1030 is under development for the treatment of hepatocellular carcinoma, lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SOT-102 in Metastatic Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SOT-102 in Metastatic Pancreatic Cancer Drug Details:SON-102 is under development for the treatment of  gastric adenocarcinoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SOT-102 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SOT-102 in Gastric Cancer Drug Details:SON-102 is under development for the treatment of  gastric adenocarcinoma or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOXR-1030 in Merkel Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOXR-1030 in Merkel Cell Carcinoma Drug Details: BOXR-1030 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NT-175 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NT-175 in Non-Small Cell Lung Cancer Drug Details: NT-175 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – It-hMSC in Ageing
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.It-hMSC in AgeingDrug Details:Stem cell therapy (Stemedyne-MSC) is under development for the treatment of non-ischemic heart...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOXR-1030 in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BOXR-1030 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details:BOXR-1030 is under development for the treatment of hepatocellular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOXR-1030 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BOXR-1030 in Solid Tumor Drug Details:BOXR-1030 is under development for the treatment of hepatocellular carcinoma, lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-328 in Pancreatic Cancer Drug Details:HPN-328 is under development for the treatment of small-cell lung cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SOT-102 in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SOT-102 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:SON-102 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Demplatin Pegraglumer in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Demplatin Pegraglumer in Oropharyngeal Cancer Drug Details: Demplatin pegraglumer (Cisplatin, NC-6004, Nanoplatin) is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.